Linked Life Data

6352639

Source:http://linkedlifedata.com/resource/pubmed/id/6352639

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1983-11-23
pubmed:abstractText
Intravenous ceftazidime (140 mg/kg/day for 14 days) was used in 28 consecutive admissions for severe respiratory infections in children and young adults with cystic fibrosis. In 20 cases ceftazidime was the sole antibiotic, but in the first eight cases it was accompanied by oral flucloxacillin. Pseudomonas aeruginosa was present in all cases, accompanied by Staphylococcus aureus in seven. Both organisms were sensitive to ceftazidime (MIC 0.12 to 8) and no case of ceftazidime resistance was seen, not even in one patient who received six courses. One patient, admitted moribund, died after only one dose had been given, his death being unconnected with the drug. In the other 27 courses there was an excellent clinical response, judged to be as good as our former high dosage carbenicillin and tobramycin combination though with much greater patient acceptability.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0305-7453
pubmed:author
pubmed:issnType
Print
pubmed:volume
12 Suppl A
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
337-40
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
Ceftazidime - a significant advance in the treatment of cystic fibrosis.
pubmed:publicationType
Journal Article